Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from VYNE Therapeutics ( (VYNE) ) is now available.
On December 17, 2025, VYNE Therapeutics and Yarrow Bioscience announced a definitive merger agreement resulting in the creation of a combined entity operating as Yarrow Bioscience, Inc. This merger positions the company to advance Yarrow’s lead program, YB-101, a first-in-class thyroid-stimulating hormone receptor antibody aimed at treating Graves’ disease and thyroid eye disease. Supported by $200 million in pre-closing financings, the combined company’s operations are expected to be funded through 2028, including multiple clinical trials scheduled to begin globally. The merger, approved unanimously by both companies’ boards, signifies a strategic pivot for VYNE to bolster its stockholder value and Yarrow’s pipeline, with leadership from Yarrow executives and significant backing from industry-leading investors.
The most recent analyst rating on (VYNE) stock is a Hold with a $0.36 price target. To see the full list of analyst forecasts on VYNE Therapeutics stock, see the VYNE Stock Forecast page.
Spark’s Take on VYNE Stock
According to Spark, TipRanks’ AI Analyst, VYNE is a Neutral.
VYNE Therapeutics faces substantial financial and operational challenges, with persistent unprofitability and cash flow issues being the most significant concerns. The recent Nasdaq non-compliance notice further exacerbates the risk profile, overshadowing any short-term technical stability. The negative valuation metrics highlight the company’s struggle to deliver shareholder value.
To see Spark’s full report on VYNE stock, click here.
More about VYNE Therapeutics
VYNE Therapeutics is a clinical-stage biopharmaceutical company specializing in therapies for inflammatory and immune-mediated conditions, leveraging its proprietary BET inhibitors under the InhiBET™ platform. Yarrow Bioscience is a clinical-stage biotechnology company focused on developing treatments for autoimmune thyroid diseases, with its lead candidate YB-101 targeting thyroid disorders such as Graves’ disease and thyroid eye disease.
Average Trading Volume: 1,953,925
Technical Sentiment Signal: Sell
Current Market Cap: $13.4M
For detailed information about VYNE stock, go to TipRanks’ Stock Analysis page.